Meeting
2012 ASCO Annual Meeting
The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Authors
Joel W. Neal
Stanford University, Palo Alto, CA
Joel W. Neal , Nathan A. Pennell , Ramaswamy Govindan , Michael Lanuti , Rachel Pam Greenerger Rosovsky , Rebecca Suk Heist , Alice Tsang Shaw , Jennifer S. Temel , Alona Muzikansky , Pasi A. Janne , Thomas James Lynch , Christopher G. Azzoli , Lecia V. Sequist
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
00567359
Citation
J Clin Oncol 30, 2012 (suppl; abstr 7010)
DOI
10.1200/jco.2012.30.15_suppl.7010
Abstract #
7010
Poster Bd #
2
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
The SELECT trial: A multicenter phase II trial of adjuvant erlotinib (E) in patients with resected, early-stage non-small cell lung cancer (NSCLC) and confirmed mutations in the epidermal growth factor receptor (EGFR).
First Author: N. A. Pennell
First Author: Karen L. Reckamp
Poster
2014 ASCO Annual Meeting
A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC).
First Author: Joel W. Neal
Poster
2013 ASCO Annual Meeting
Clinical implications of routine testing for epidermal growth factor receptor (EGFR) mutations in patients with nonsquamous non-small cell lung cancer (NSCLC).
First Author: Hui Zhu